gilead sanofi - Search News

News

Sanofi, Gilead Sciences and Kymera

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

Fierce Biotech · 1d

Kymera suffers Sanofi setback but secures $750M Gilead deal

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 million deal with Gilead Sciences.

BioPharma Dive · 1d

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

Zacks Investment Research on MSN19h

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Fierce Pharma12h

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride month

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results